nicotine has been researched along with solabegron in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cellek, S; Hafsi, N; Kober, OI; Langer, R; Lee, K; Li, Q; Michel, K; Schemann, M; Wollmann, J; Zeller, F | 1 |
1 other study(ies) available for nicotine and solabegron
Article | Year |
---|---|
The beta3-adrenoceptor agonist GW427353 (Solabegron) decreases excitability of human enteric neurons via release of somatostatin.
Topics: Action Potentials; Adipocytes; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-3 Receptor Antagonists; Aged; Aniline Compounds; Benzoates; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Female; Ganglionic Stimulants; Humans; In Vitro Techniques; Intestines; Male; Middle Aged; Myenteric Plexus; Neurons; Nicotine; Propanolamines; Receptors, Adrenergic, beta-3; Somatostatin; Submucous Plexus | 2010 |